The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies
June 27, 1999
A retrospective study of PI- and d4T-naïve patients who received ritonavir (RTV) + saquniavir (SQV) therapy or RTV + SQV + d4T therapy found no association between d4T use and elevated triglycerides or total cholesterol. While triglyceride and cholesterol levels increased for both treatment arms, Wit and colleagues found no differences in triglyceride or cholesterol levels between the two regimens at follow up. A sub-analysis of patients who were either antiretroviral-experienced or antiretroviral-naïve, prior to initiating their assigned regimen, also found no differences in these parameters. The authors concluded that the addition of d4T to a RTV + SQV regimen was not associated with an increased risk of hyperlipidemia.Abstract: Stavudine (d4T) Use Is Not Associated with an Incremental Risk of Hyperlipidemia During Treatment with HIV-1 Protease Inhibitors (PIs)
Authored by: F.W.N.M. Wit, E.H. Gisolf, L.M.M. Oostweegel, G.W. Weverling, J.M.A. Lange, P. Reiss, and S.A. Danner
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.